

Applicants: Ron S. Israeli et al.  
Serial No.: 08/470,735  
Filed : June 6, 1995  
Page 2

- 2126
- 108  
--~~105~~. (New) A therapeutic agent comprising the antibody of claim ~~102~~<sup>105</sup> and a cytotoxic agent conjugated thereto.--
- 109  
--~~106~~. (New) The therapeutic agent of claim ~~105~~<sup>108</sup>, wherein the cytotoxic agent is either a radioisotope or toxin.--
- 110  
--~~107~~. (New) A prostate cancer imaging agent comprising the antibody of claim ~~102~~<sup>105</sup> and a radioisotope conjugated thereto.--
- 111  
--~~108~~. (New) A composition comprising an effective imaging amount of the antibody of claim ~~102~~<sup>105</sup> and a pharmaceutically acceptable carrier.--
- 112  
--~~109~~. (New) A method of imaging prostate cancer in a subject which comprises administering to the subject the antibody of claim 102 which is labeled with an imaging agent under conditions permitting formation of a complex between the antibody and the cell surface of the prostate specific membrane antigen.--
- 113  
--~~110~~. (New) An antibody which binds to prostate specific membrane antigen other than the known 7E11-C5 antibody.--
- CI  
CONT

#### REMARKS

Claims 93-96 and 98-101 were pending and under examination in the subject application. Applicants have hereinabove canceled claim 93 without prejudice to their right to pursue the subject matter in a later-filed application. Applicants have hereinabove added new claims 102-110. Support for claim 102-110 may be found inter